Is amikacin more ototoxic than tobramycin or gentamicin?

Is Amikacin More Ototoxic Than Tobramycin or Gentamicin?

Amikacin causes more cochlear (hearing) toxicity than tobramycin or gentamicin, but causes less vestibular toxicity than these agents. 1, 2

Comparative Ototoxicity Profile

Cochlear vs. Vestibular Toxicity Patterns

The aminoglycosides differ substantially in their pattern of inner ear damage:

• Amikacin is primarily cochleotoxic, meaning it preferentially damages hearing rather than balance function 2
• Gentamicin and streptomycin are primarily vestibulotoxic, causing more dizziness and balance problems than hearing loss 2
• Tobramycin shows less overall toxicity than gentamicin, though the difference is only statistically significant for vestibular toxicity 3

Quantified Hearing Loss Risk

The evidence demonstrates amikacin's substantial risk to hearing:

• High-frequency hearing loss occurred in 24% of patients receiving amikacin in one prospective study, though no patients developed conversational hearing loss 1, 4
• Among patients with peak serum levels exceeding 32 μg/mL, 57% developed cochlear damage 4
• Among patients with trough levels exceeding 10 μg/mL, 55% developed cochlear damage 4
• A literature review found only 1.5% hearing loss with amikacin, though this lower figure likely reflects variable monitoring practices 1

Comparative Nephrotoxicity

Beyond hearing, amikacin also carries higher kidney toxicity risk:

• Amikacin is more nephrotoxic than streptomycin, with renal impairment occurring in 8.7% of amikacin-treated patients versus 2% with streptomycin 1
• Streptomycin was least associated with hearing loss among amikacin, kanamycin, and streptomycin 1

Risk Factors That Amplify Amikacin Ototoxicity

The following factors substantially increase your patient's risk of hearing loss:

• Cumulative dose and duration of therapy are the strongest predictors—patients receiving a mean total dose of 24g versus 9.6g had significantly higher rates of cochlear damage 4
• Treatment duration exceeding 10 days significantly increases toxicity risk 3
• Older age is consistently associated with ototoxicity 1, 5
• Previous aminoglycoside exposure increases subsequent ototoxicity risk 4
• Concurrent loop diuretics (furosemide, ethacrynic acid) potentiate ototoxicity and must be avoided 5, 6
• Renal impairment increases both ototoxicity and nephrotoxicity risk through drug accumulation 1, 5

Critical Monitoring Requirements

Given amikacin's high cochleotoxicity, aggressive monitoring is essential:

• Obtain baseline audiometry before initiating therapy in all patients who can be tested 5, 6
• Perform monthly audiometry until aminoglycoside treatment ceases 5, 6
• Ototoxicity is defined as 20 dB loss from baseline at any one test frequency OR 10 dB loss at any two adjacent test frequencies 5, 6
• Target trough levels must remain <5 mg/L for amikacin 5, 7
• Monitor renal function monthly and adjust dosing in renal impairment 7

Immediate Action Upon Detection

If ototoxicity is detected on audiogram, discontinue amikacin immediately—hearing loss already occurred is likely permanent 5, 6

Patients must be instructed to stop treatment immediately and contact their prescriber if they develop tinnitus, vertigo, loss of balance, hearing loss, or auditory disturbances 5, 6

Dosing Adjustments to Minimize Risk

For patients over 59 years or with renal impairment:

• Reduce dose to 10 mg/kg per day (maximum 750 mg) for elderly patients 1, 6
• In renal insufficiency, maintain the 12-15 mg/kg dose but reduce frequency to 2-3 times weekly rather than reducing the milligram dose, which may compromise efficacy 1, 6
• Never reduce the milligram dose below 12-15 mg/kg when extending intervals, as smaller doses reduce the concentration-dependent bactericidal effect 1, 6

Common Pitfalls to Avoid

• Never combine multiple aminoglycosides—this increases toxicity without clinical benefit 5, 6
• Do not delay audiometry until symptoms appear—damage may already be irreversible 5
• Patient-reported symptoms alone are unreliable—objective audiometry is essential 5
• Avoid amikacin in second or third trimester of pregnancy due to risk of fetal vestibular or auditory nerve damage 5, 6

Clinical Bottom Line

While amikacin is more cochleotoxic than tobramycin or gentamicin, the choice between aminoglycosides should be driven by antimicrobial susceptibility patterns and infection severity. When amikacin is necessary, meticulous attention to dosing, therapeutic drug monitoring, and serial audiometry can help detect toxicity early, though prevention through dose limitation and duration minimization remains the most effective strategy. 1, 4